CN106038566B - A kind of pharmaceutical composition and its application for curing gastric cancer - Google Patents
A kind of pharmaceutical composition and its application for curing gastric cancer Download PDFInfo
- Publication number
- CN106038566B CN106038566B CN201610401467.6A CN201610401467A CN106038566B CN 106038566 B CN106038566 B CN 106038566B CN 201610401467 A CN201610401467 A CN 201610401467A CN 106038566 B CN106038566 B CN 106038566B
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- pharmaceutical composition
- cucoline
- buddhist nun
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of pharmaceutical compositions and its application for curing gastric cancer, belong to pharmaceutical technology field.In order to overcome the side effect of existing treatment gastric cancer medicament larger, the not strong technical deficiency of drug effect, the present invention provide it is a kind of treat gastric cancer medicament composition, be made of Ah pa for Buddhist nun and cucoline.Two kinds of active pharmaceutical ingredients have significant synergistic effect in inhibition human gastric cancer MGC-803 body in terms of proliferation, to play good therapeutic effect to gastric cancer.
Description
Technical field
The present invention relates to a kind of pharmaceutical compositions and its application for curing gastric cancer, belong to pharmaceutical technology field.
Background technique
Gastric cancer is derived from the malignant tumour of gastric epithelial, is one of most common malignant tumour of alimentary canal, and morbidity can
Can be related with the factors such as living environment, depressed emotion, feeding desorder, stomach chronic disease long-time stimulus, account for stomach malignancy
95%, shared ratio is different with different regions in human tumor, and typically about 10~30%, it is seen that gastric cancer is to threaten the mankind
A kind of common disease of health.The symptom of gastric cancer and precancerous lesion hides and without specificity, therefore early carcinoma of stomach is difficult to find.It is true
On, the gastric cancer of China only 5%~10% can be early diagnosed.And gastric cancer middle and advanced stage patient, body are relatively weak, organ function
It can decline, lassitude, immunity degradation, the ability that immunocyte resists stomach cancer cell infringement is poor, and stomach cancer cell is caused to spread
Accelerating, patient pain deepens, and is easy to appear the transfer case of gastric cancer middle and advanced stage, and situations such as hepatic metastases, Bone tumour occurs in cancer cell,
Make state of an illness high progression.
Traditional curing gastric cancer mode performs the operation, radiotherapy, chemotherapy, is all the western medical treatment method of gastric cancer.The treatment of doctor trained in Western medicine is past
It is past all to there is side effect.It performs the operation very big for the loss of patients with gastric cancer body, is easy to keep originally weak patient body more empty
It is weak, internal remaining cancer cell more fast-growth slow so as to cause post-operative recovery.Chemicotherapy has using to stomach cancer cell
There are the radioactive ray of killing effect, chemicals are the therapeutic modalities of " combatting poison with poison ".But chemicotherapy is killing the same of cancer cell
When, certain injury can be also resulted in human normal immunocyte, normal organ, Nausea and vomiting occur, without diseases such as appetite, alopecias
Shape, these are all the side effects of western medical treatment.
On December 13rd, 2014, the small molecule targeted drug " methanesulfonic acid for being used to treat late gastric cancer of Chinese independent development
A Pa replaces Buddhist nun's piece " the approval listing of state food Drug Enforcement Administration is obtained, this is that the great new drug initiative science and technology of China national is great specially
Under item is supported, in the another important breakthrough that therapeutic field of tumor obtains.A Pa is a kind of molecular targeted anti-tumor drug for Buddhist nun, by
One kind new medicine of Hengrui Medicine Co., Ltd., Jiangsu Prov.'s independent research, the small molecule blood vessel endothelium for possessing independent intellectual property right are raw
Long factor tyrosine kinase inhibitor.A Pa can be used for treating advanced stage non-squama non-small cell lung cancer, gastric cancer, liver cancer, cream for Buddhist nun's piece
Gland cancer.Chinese invention patent 201480036218.0 discloses eribulin and the happy conjoint therapy cut down for Buddhist nun as treating cancer
Purposes.The conjoint therapy has the effect of certain in the treatment of cancer, but the two is used in combination rear toxic side effect and increases, and uses
There are hidden danger for medicine safety.The prior art is shown, less side effects when Chinese patent drug or traditional Chinese medicinal components are for curing gastric cancer, but in
It is but and unsatisfactory at the medication effect of drug.
Summary of the invention
In order to overcome the side effect of existing treatment gastric cancer medicament larger, the unendurable technical deficiency of drug effect, the present invention is mentioned
Gastric cancer medicament composition is treated for a kind of, is made of happy cut down for Buddhist nun and cucoline.Two kinds of active pharmaceutical ingredients are inhibiting people's stomach
Proliferation aspect has significant synergistic effect in cancer MGC-803 body, to play good therapeutic effect to gastric cancer.
To achieve the goals above, the invention adopts the following technical scheme：
A kind of pharmaceutical composition for treating gastric cancer, is made of following active constituent：
1) Ah pa replaces Buddhist nun；
2) cucoline.
It is 1 that wherein A Pa, which replaces the weight ratio of Buddhist nun and cucoline, in described pharmaceutical composition：0.1-10, more preferably 1：5.
The present invention also provides a kind of pharmaceutical preparation for treating gastric cancer, it is by a effective amount of Ah pa for Buddhist nun, a effective amount of
The preparation that cucoline and pharmaceutically acceptable auxiliary material or complementary ingredient are prepared.Wherein, the pharmaceutical preparation is mouth
Formulation.The oral preparation is preferably its capsule, tablet, granule.
In the pharmaceutical preparation for the treatment of gastric cancer described above, the content of cucoline is 1-2000mg in each preparation unit.
Purposes of the aforementioned pharmaceutical compositions in preparation treatment gastric cancer medicament is also claimed in the present invention.The embodiment of the present invention
7 displays, compound group of the present invention and single medicine group have inhibiting effect to human gastric cancer MGC-803 in vivo, wherein compound of the present invention
No matter the tumour inhibiting rate of group is compared with Ah pa is for Buddhist nun's list medicine group or cucoline list medicine group compares the difference for all having conspicuousness, also
It is to say, two kinds of drugs have significant synergistic effect in inhibition human gastric cancer MGC-803 body in terms of proliferation.Wherein compound can be effective
Inhibit the growth of stomach neoplasm, tumour inhibiting rate reaches as high as 69.5%.
The present invention has following unexpected technical effect outstanding compared with prior art：
1）Compound group of the present invention and single medicine group have inhibiting effect to human gastric cancer MGC-803 in vivo, wherein the present invention
No matter the tumour inhibiting rate of compound group is compared with Ah pa is for Buddhist nun's list medicine group or cucoline list medicine group compares the difference for all having conspicuousness,
That is, two kinds of drugs have significant synergistic effect in inhibition human gastric cancer MGC-803 body in terms of proliferation.Wherein compound can
Effectively inhibit the growth of stomach neoplasm, tumour inhibiting rate reaches as high as 69.5%.
2）The dosage that Ah pa replaces Buddhist nun can be significantly reduced in the two while therapeutic effect enhancing after being used in combination, from
And bleeding risk is reduced, improve its drug safety.
Specific embodiment
The present invention is further described by the following examples, but these embodiments are illustrative of the invention, and should not be understood
For any limitation on the scope of the present invention.
The preparation of 1 composite tablet of embodiment
| Cucoline | 1g |
| A Pa replaces Buddhist nun | 10g |
| Microcrystalline cellulose | 45g |
| Starch | 30g |
| 15% starch slurry | In right amount |
| Magnesium stearate | 2.0g |
Preparation process：Cucoline and A Pa are uniformly mixed for Buddhist nun with microcrystalline cellulose excipients, starch, are added suitable
Then 15% starch slurry softwood crosses the granulation of 16 meshes.Wet granular crosses 16 mesh sieves, sifts out dry granular in 60 DEG C of dryings, dry particl
In fine powder, with magnesium stearate mix, then again with dry particl mix, tabletting to get.
The preparation of 2 composite tablet of embodiment
| Cucoline | 10g |
| A Pa replaces Buddhist nun | 1g |
| Amylum pregelatinisatum | 90g |
| Lactose | 50g |
| 15% starch slurry | In right amount |
| Superfine silica gel powder | 1.5g |
Preparation process：In addition to component is different, preparation process is the same as technique described in embodiment 1.
The preparation of 3 compound dispersed tablet of embodiment
| Cucoline | 10g |
| A Pa replaces Buddhist nun | 2g |
| Croscarmellose sodium | 12g |
| Microcrystalline cellulose | 160g |
| Polyvinylpyrrolidone | 6g |
| 60% ethanol solution of 5%PVP | In right amount |
| Superfine silica gel powder | 5g |
Preparation process：Cucoline, Ah pa are weighed by recipe quantity for Buddhist nun, using microcrystalline cellulose as filler, cross-linked carboxymethyl
Sodium cellulosate, polyvinylpyrrolidone are disintegrating agent, and 60% ethanol solution of 5%PVP is binder, and superfine silica gel powder is glidant,
With fluid-bed marumerization, then tabletting to get.
The preparation of 4 composite tablet of embodiment
| Cucoline | 50g |
| A Pa replaces Buddhist nun | 5g |
| Amylum pregelatinisatum | 90g |
| Lactose | 50g |
| 15% starch slurry | In right amount |
| Superfine silica gel powder | 1.5g |
Preparation process：It is prepared by technique described in embodiment 2 to obtain the final product.
The preparation of 5 compound granule of embodiment
| Cucoline | 40g |
| A Pa replaces Buddhist nun | 8g |
| Starch | 180g |
| Dextrin | 50g |
| Cane sugar powder | 60g |
| 80% ethyl alcohol | In right amount |
Preparation process：Cucoline, the Ah pa of recipe quantity is weighed to be uniformly mixed for Buddhist nun, starch, dextrin, cane sugar powder.It will separately fit
80% ethyl alcohol of amount is incorporated in mixed-powder, is uniformly mixed, wet grain, 60 DEG C of left and right trunks are made by 18 mesh nylon mesh in softwood processed
It is dry, 20 mesh sieves, packing to get.
The preparation of 6 compound granule of embodiment
| Cucoline | 50g |
| A Pa replaces Buddhist nun | 50g |
| Starch | 180g |
| Dextrin | 50g |
| Cane sugar powder | 60g |
| 80% ethyl alcohol | In right amount |
Preparation process：Cucoline, starch, dextrin, the cane sugar powder for weighing recipe quantity are uniformly mixed.Separately by suitable 80% second
Alcohol is incorporated in mixed-powder, is uniformly mixed, wet grain, 60 DEG C or so dryings, 20 meshes are made by 18 mesh nylon mesh in softwood processed
Whole grain, packing to get.
To the inhibiting effect of human gastric cancer MGC-803 in the pharmaceutical composition body of the present invention of embodiment 7
1. tumor cell line is used in test
MGC-803 human stomach cancer cell line is purchased from Shanghai Inst. of Life Science, CAS
2. experimental animal
BALB/c nude mice Beijing Vital River Experimental Animals Technology Co., Ltd. production licence number：SCXK（Capital）
2012-0001
3. test method
The culture of human gastric cancer MGC-803 cell routine, passage, logarithmic growth phase cell, adjust viable cell concentrations be 1 ×
107A/0.2 ml/ of ml only, is inoculated in nude mice oxter.After after nude mice oxter, tumour is grown, by tumor bearing nude mice according to tumor size
8 groups are randomly divided into, off-test after successive administration 60 days.
Model group gives same amount of normal saline.
A Pa replaces low group of Buddhist nun：Stomach-filling gives Ah pa for Buddhist nun 0.5mg/kg;
A Pa replaces high group of Buddhist nun：Stomach-filling gives Ah pa for Buddhist nun 5mg/kg;
Low group of cucoline：Cucoline 0.5mg/kg is given in stomach-filling；
High group of cucoline：Cucoline 5mg/kg is given in stomach-filling；
1 group of compound：Stomach-filling gives Ah pa for Buddhist nun 0.5mg/kg+ cucoline 5mg/kg；
2 groups of compound：Stomach-filling gives Ah pa for Buddhist nun 5mg/kg+ cucoline 0.5mg/kg；
3 groups of compound：Stomach-filling gives Ah pa for Buddhist nun 0.5mg/kg+ cucoline 2.5mg/kg
Animal is put to death after 24 h of last dose, tumor is taken to weigh, calculates average tumour inhibiting rate（Inhibition rate, I）, public
Formula is as follows：I=(1-administration group average knurl weight/model group average knurl weight) × 100 %.
4. data statistics and processing method
Experimental data uses spss16.0, single factor test variance one way ANOV analysis, p<0.05 has statistics for difference
Meaning.
5. test result
Inhibiting effect result of the compound of the present invention of table 1 to human gastric cancer MGC-803
| Group | Number of animals（Only） | Knurl weight（g） | Tumour inhibiting rate（%） |
| Model group | 10 | 0.985±0.176 | |
| A Pa replaces low group of Buddhist nun | 10 | 0.624±0.029 | 36.6 |
| A Pa replaces high group of Buddhist nun | 10 | 0.581±0.031 | 41.0 |
| Low group of cucoline | 10 | 0.812±0.036 | 17.6 |
| High group of cucoline | 10 | 0.768±0.068 | 22.0 |
| 1 group of compound | 10 | 0.476±0.128# | 51.7 |
| 2 groups of compound | 10 | 0.401±0.123# | 59.3 |
| 3 groups of compound | 10 | 0.300±0.058# | 69.5 |
Compared with model group,#, P < 0.05
1 experimental result of table shows that compound group of the present invention and single medicine group have inhibition to make human gastric cancer MGC-803 in vivo
With no matter wherein the tumour inhibiting rate of compound group of the present invention is compared with Ah pa is for Buddhist nun's list medicine group or cucoline list medicine group is compared and all had
The difference of conspicuousness, that is to say, that two kinds of drugs in terms of proliferation there is significant collaboration to make in inhibition human gastric cancer MGC-803 body
With.Wherein the growth of stomach neoplasm can be effectively suppressed in compound, and tumour inhibiting rate reaches as high as 69.5%.
Claims (6)
1. a kind of pharmaceutical composition for curing gastric cancer, is made of following active constituent：
1) Ah pa replaces Buddhist nun；
2) cucoline；A Pa is 1 for the weight ratio of Buddhist nun and cucoline in described pharmaceutical composition：0.1-10.
2. pharmaceutical composition according to claim 1, which is characterized in that A Pa replaces Buddhist nun and sinomenium acutum in described pharmaceutical composition
The weight ratio of alkali is 1：5.
3. pharmaceutical composition according to claim 1, which is characterized in that described pharmaceutical composition is its oral preparation.
4. pharmaceutical composition according to claim 3, which is characterized in that the oral preparation of the pharmaceutical composition is it
Capsule, tablet or granule.
5. pharmaceutical composition according to claim 3, which is characterized in that the content of cucoline is 1- in each preparation unit
2000mg。
6. purposes of the pharmaceutical composition described in claim 1 in preparation treatment gastric cancer medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610401467.6A CN106038566B (en) | 2016-06-10 | 2016-06-10 | A kind of pharmaceutical composition and its application for curing gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610401467.6A CN106038566B (en) | 2016-06-10 | 2016-06-10 | A kind of pharmaceutical composition and its application for curing gastric cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106038566A CN106038566A (en) | 2016-10-26 |
| CN106038566B true CN106038566B (en) | 2018-11-27 |
Family
ID=57170527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610401467.6A Active CN106038566B (en) | 2016-06-10 | 2016-06-10 | A kind of pharmaceutical composition and its application for curing gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106038566B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202033189A (en) * | 2018-11-21 | 2020-09-16 | 美商Ｌｓｋ生命伙伴股份有限公司（亦以艾勒華療法公司名義營業） | Pharmaceutical methods |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033906A2 (en) * | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| CN102579444A (en) * | 2012-01-21 | 2012-07-18 | 张有成 | Application of sinomenine in preparation process of drugs inhibiting invasion and metastasis of tumors |
| CN104072411A (en) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | Mesylate C crystal form of amide derivatives as well as preparation method and application thereof |
-
2016
- 2016-06-10 CN CN201610401467.6A patent/CN106038566B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033906A2 (en) * | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| CN102579444A (en) * | 2012-01-21 | 2012-07-18 | 张有成 | Application of sinomenine in preparation process of drugs inhibiting invasion and metastasis of tumors |
| CN104072411A (en) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | Mesylate C crystal form of amide derivatives as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 青藤碱抗炎免疫与抗肿瘤作用研究新进展;孙越华等;《中国药理学通报》;20150722;第31卷(第8期);第1040-1043页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106038566A (en) | 2016-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101891505B1 (en) | Use of anhydroicaritin in preparing medicine for preventing or treating decrease in blood cells | |
| CN104257844B (en) | A kind of Chinese powder medicine treating porcine hyperthermia and preparation technology thereof | |
| JP2006182679A (en) | Preventing and treating agent of stress gastritis | |
| CN106038566B (en) | A kind of pharmaceutical composition and its application for curing gastric cancer | |
| CN105343056A (en) | Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application | |
| CN114939122B (en) | Combined antitumor pharmaceutical composition derived from natural plants | |
| JP2001518481A (en) | Serotonin-containing preparations for oral administration and methods of use | |
| CN102824595A (en) | Traditional Chinese medicine composition for treating cancer ache | |
| CN111265599A (en) | Application of lycopene and grape seed composition in preparation of medicine for treating arthritis | |
| CN105832732A (en) | Pharmaceutical composition for treatment of gastric cancer and application of pharmaceutical composition for treatment of gastric cancer | |
| CN112691107B (en) | Pharmaceutical composition and application thereof | |
| US11793852B2 (en) | Application of Longhu Rendan in preparing medicament for preventing and/or treating liver fibrosis | |
| CN109731019B (en) | A composition with chemotherapy synergistic effect comprises components, preparation and application | |
| WO2003015807A1 (en) | Side effct-relieving agents and/or hypoglycemic effect enhancers for thiazolidine derivatives | |
| CN102225067B (en) | Pharmaceutical composition for treating stomach cancer | |
| CN104688722B (en) | Purposes of the epimedium aglucone in preparation prevention or treatment bone marrow suppression drug | |
| CN103800341B (en) | The combination medicine of anti-curing oncoma | |
| TWI469784B (en) | Therapeutic compositoin for treating cancers | |
| CN105832739A (en) | Medicine composition with dasatinib and application of medicine composition | |
| AU2020103468A4 (en) | The Traditional Chinese Medicine Composition And Preparing Method For Treating Depression | |
| CN111419853B (en) | Cucurbitacin and ibrutinib composition for treating breast cancer | |
| CN110237061A (en) | Butyric acid compound is inhibiting the application in long-chain non-coding RNA-H19 | |
| CN111388665B (en) | Compound for treating tumor and preparation and application thereof | |
| CN111467408B (en) | Traditional Chinese medicine composition for clearing heat and removing toxicity, nourishing yin and reducing fire and preparation method thereof | |
| CN110507623B (en) | Composition containing levothyroxine sodium and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Pengfei Inventor after: Gao Die Inventor after: Wang Fangjun Inventor after: Shen Weidong Inventor after: Deng Lichun Inventor after: Other inventors request not to publish names Inventor before: The inventor has waived the right to be mentioned |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20181018 Address after: 214400 163 Shoushan Road, Jiangyin, Wuxi, Jiangsu Applicant after: JIANGYIN PEOPLE'S HOSPITAL Address before: 266000 1 buildings in No. 713-1 Xiangjiang Road, Huangdao District, Qingdao, Shandong. Applicant before: Qingdao Keruiyuan Biotechnology Co., Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |